Interval breast cancer risk associations with breast density, family history and breast tissue aging

Tuong L. Nguyen1,8, Shuai Li1,8, Gillian S. Dite1, Ye K. Aung1, Christopher F. Evans1, Ho N. Trinh1, Laura Baglietto2, Jennifer Stone3, Yun-Mi Song4, Joonho Sung5,6, Dallas R. English1,7, Mark A. Jenkins1, Pierre-Antoine Dugué1,7,8, Roger L. Milne1,7,8, Melissa C. Southey8, Graham G. Giles1,7,8, Malcolm C. Pike9 and John L. Hopper1

1Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia
2Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
3Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, WA, Australia
4Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
5Department of Epidemiology School of Public Health, Seoul National University, Seoul, South Korea
6Institute of Health and Environment, Seoul National University, Seoul, South Korea
7Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia
8Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
9Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

Interval breast cancers (those diagnosed between recommended mammography screens) generally have poorer outcomes and are more common among women with dense breasts. We aimed to develop a risk model for interval breast cancer. We conducted a nested case–control study within the Melbourne Collaborative Cohort Study involving 168 interval breast cancer patients and 498 matched control subjects. We measured breast density using the CUMULUS software. We recorded first-degree family history by questionnaire, measured body mass index (BMI) and calculated age-adjusted breast tissue aging, a novel measure of exposure to estrogen and progesterone based on the Pike model. We fitted conditional logistic regression to estimate odds ratio (OR) or odds ratio per adjusted standard deviation (OPERA) and calculated the area under the receiver operating characteristic curve (AUC). The stronger risk associations were for unadjusted percent breast density (OPERA = 1.99; AUC = 0.66), more so after adjusting for age and BMI (OPERA = 2.26; AUC = 0.70), and for family history (OR = 2.70; AUC = 0.56). When the latter two factors and their multiplicative interactions with age-adjusted breast tissue aging (p = 0.01 and 0.02, respectively) were fitted, the AUC was 0.73 (95% CI 0.69–0.77), equivalent to a ninefold interquartile risk ratio. In summary, compared with using dense breasts alone, risk discrimination for interval breast cancers could be doubled by instead using breast density, BMI, family history and hormonal exposure. This would also give women with dense breasts, and their physicians, more information about the major consequence of having dense breasts—an increased risk of developing an interval breast cancer.

*T.L.N. and S.L. contributed equally to this work

Additional Supporting Information may be found in the online version of this article.

Key words: body mass index, breast density, family history, interval breast cancer, Pike’s model of breast tissue aging

Abbreviations: AUC: area under the receiver operating characteristic curve; BIC: Bayesian Information Criterion; BMI: body mass index; CC: craniocaudal; CI: confidence interval.; LL: log-likelihood; OPERA: odds per adjusted standard deviation

Conflict of interest: GSD has received some funding from Genetic Technologies Ltd. for work unrelated to this article.

This article is dedicated to the memory of Nancy Cappello and her achievements in raising awareness of the role of breast density in masking breast tumors

Grant sponsor: Australian National Health and Medical Research Council; Grant numbers: 1074383, 209057, 251533, 396414, 504711;
Grant sponsor: Cure Cancer Australia - Cancer Australia; Grant number: 1159399; Grant sponsor: US National Institutes of Health/National Cancer Institute Cancer Institute; Grant number: P30CA008748

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1002/ijc.32731

History: Received 29 Jul 2019; Accepted 27 Sep 2019; Online 12 Nov 2019

Correspondence to: Professor John Hopper, E-mail: j.hopper@unimelb.edu.au

Int. J. Cancer: 147, 375–382 (2020) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
What’s new?
Breast cancers that are detected between regular screening intervals are more aggressive and have poorer outcomes than screen-detected tumors but no valid risk model exists to predict “interval” breast cancers. Here the authors combined breast density with other breast cancer risk factors such as body mass index, family history and a novel measure of age-adjusted hormonal exposure. Applying this to more than 150 women with interval breast cancer, they find that risk discrimination can be doubled with the combination of factors as compared with just using breast density alone, thus improving risk predictions and clinical recommendations for breast screening procedures.

Introduction
Interval breast cancers are diagnosed after a negative screen but before the next recommended screen. Interval cancers are important for many reasons, not the least because women diagnosed with interval cancers have poor outcomes.1 Compared with screen-detected breast cancers, interval breast cancers are generally larger and have a more aggressive phenotype.2 Interval cancers have an incidence of 10–20 per 10,000 women attending two-yearly mammographic screening3 and represent 20–30% of all breast cancers diagnosed in those women.4

A risk model for interval cancers would be important for breast cancer control. Women could be triaged according to their risk for tailored screening, a concept being tested by the Women Informed to Screen Depending On Measures of risk (WISDOM) trial.6 Triaging could address the on-going need to improve the cost-effectiveness of screening, minimize harms7 and help mitigate the problem of dense breasts masking tumors,8–10 an issue made prominent by the late Nancy Cappello.11

Dense breasts have become an important issue in the US with most states passing laws that require women with dense breasts to be notified and encouraged to discuss supplemental screening and concerns with their health care provider. More than 25 million US women aged 40–74 years (43%) have dense breasts defined by the Breast Imaging Reporting and Data System’s (BI-RADS) categories c and d.12,13 Breast density notification within the US typically depends solely on BI-RADS classifications, with no consideration of other risk factors or demographics.14 Kerlikowske et al.4 showed that better prediction of interval breast cancer risk can be achieved by including other information, although in doing so, they assumed that the risk factors for breast cancer, in general, apply to interval cancers with the same risk gradient.

In this article, we define breast density as the proportion of the breast image that is mammographically dense, defined by the light or bright areas on a mammogram. Women with greater breast density are more likely to be diagnosed with interval cancers,15,16 likely due to the reduced ability of radiologists to detect tumors in dense regions (masking).15,17 Breast density, once adjusted for age and body mass index (BMI) due to negative confounding, is implicated in risk of breast cancer overall.18

The association of breast density with interval cancers could be due to, or amplified by, a combination of factors related to risk and masking. For example, having a mother or sister with breast cancer has perhaps an even stronger risk association with interval breast cancers than it does with screen-detected cancers.2,15

To better inform women of the consequences of their breast density, we aimed to develop a risk model for interval breast cancer based on breast density and other breast cancer risk factors by conducting a matched case–control study nested within a prospective cohort. We also introduced a novel measure of hormonal exposure, age-adjusted breast tissue aging. Pike et al.19 modeled age-specific breast cancer incidence as a function of breast tissue aging, which summarized the effects of exposure to estrogen and progesterone on incidence by a single measure based on reproductive and hormonally related factors. Rosner et al.20 confirmed the model and extended it to take into account having one or more full-term births (see Table 2 and fig. 4 of Rosner et al.20). We also studied these putative risk factors, individually and combined, and fitted interactions to address whether their risk associations are modified by breast density.21

Materials and Methods
Sample
We used the Melbourne Collaborative Cohort Study of adult residents of Melbourne, Australia aged 40–69 years when recruited between 1990 and 1994.22–24 We conducted a nested case–control study within the cohort of 20,444 women who were unaffected when they completed their baseline questionnaire and who, from data linkage in 2009, were found to have attended BreastScreen Victoria (BSV) at least once. BSV is part of Australia’s national breast cancer screening program, established in 1992 to offer free mammographic screening to women over 40 years of age. The target group for the screening program is women aged 50–69 years, who are invited for screening every 2 years. Incident breast cancers were defined as those diagnosed within 2 years of a negative screening at BSV16 and identified by BSV or by linkage with the population-complete Victorian Cancer Registry or the Australian Cancer Database. Incident breast cancers diagnosed less than 2 years after a negative mammogram taken at BSV were classified as interval cancers. Case patients were women diagnosed with incident interval breast cancers. Control subjects were matched to case patients on the year of birth, year of baseline interview and country of birth.16,24 Control subjects were randomly selected from women who had not been diagnosed with breast cancer at the age of diagnosis of the case patient. The study sample was 168 interval breast cancer diagnoses, with no consideration of other risk factors or demographics.
patients (148 with invasive cancer) and 498 matched control subjects (we had aimed for four control subjects per case patient but this was not always possible). The study was approved by the human research ethics committees of the University of Melbourne and Cancer Council Victoria and consent was obtained from study participants at the time of recruitment.

**Measurement of breast density**

All mammograms were screen-film and were digitized using an Array 2905 Laser Film Digitizer at 12-bit depth. Breast density was measured from the mammograms taken closest to baseline. For interval breast cancer patients, mammograms of the unaffected (contralateral) breast taken at or before diagnosis were used. We used the CUMULUS computer-assisted thresholding method to measure conventionally defined breast density. Five operators (TLN, YKA, SL, CFE and HNT) independently measured breast density blinded to the case–control status. Measurements were completed in sets of 100 mammograms. For the average of operators, the within-set repeatability was 0.95 (95% confidence interval [CI] 0.94–0.96) and the between-set repeatability was 0.95 (95% CI 0.93–0.97).

**Measurement of other risk factors**

Subjects completed interviewer-administered questionnaires at baseline that asked about age at menarche, number of full-term live births, age at each birth, breastfeeding, menopausal status, age at menopause, hormonal replacement therapy use, oral contraceptive use and alcohol consumption. Height and weight were measured using standard protocols and used to calculate BMI = weight (kg)/height (m)². Family history of breast cancer was defined as having at least one first-degree blood relative with breast cancer based on a questionnaire filled out by women at their time of screening by BSV.

**Breast tissue aging**

After Pike et al. and Rosner et al., starting at puberty, the rate of breast tissue aging is assumed to be a constant (which, without loss of generality, is taken to be 1) up until first full-term livebirth, when it decreases. Breast tissue aging decreases with subsequent live births and after menopause. The model parameters were estimated so that the area under the breast tissue aging curve to age $t$, taken to the power of 4.5, fits the age-specific incidence curve for breast cancer. We therefore defined breast tissue aging to be the area under the breast tissue age curve up to the woman’s age at baseline questionnaire; see Supplementary Material.

**Statistical methods**

For both breast density and breast tissue aging, a cube-root function gave the optimal Box–Cox power transformation to normality. Transformed breast density was adjusted for age and BMI, and transformed breast tissue aging was adjusted for age, using linear regression. The standardized adjusted

---

**Table 1. Study participant characteristics by family history**

|                      | No family history | Family history |
|----------------------|-------------------|----------------|
|                      | Cases (n = 132)   | Controls (n = 450) | Cases (n = 36) | Controls (n = 48) |
| Age at mammogram (years) | Mean (SD) | p | Mean (SD) | p | Mean (SD) | p | Mean (SD) | p |
| Age at menarche (years)      | 13.2 (1.6)   | 0.4 | 12.6 (1.4)   | 0.03 |
| Age at menopausal (years, post, n = 401) | 48.7 (5.0)   | 0.07 | 48.9 (6.0)   | 0.3 |
| Body mass index (kg/m²)     | 26.6 (5.1)   | 0.7 | 26.8 (5.9)   | 0.8 |
| Number of live births (n = 564) | 2.6 (0.9)   | 0.4 | 2.8 (0.9)   | 0.9 |
| Age at first live birth (n = 564) | 26.2 (5.0)   | 0.2 | 25.8 (3.5)   | 0.2 |
| Age at last live birth (n = 522) | 31.4 (4.7)   | 0.5 | 31.5 (3.6)   | 0.6 |
| Breast tissue aging         | 37.9 (4.8)   | 0.6 | 38.8 (4.7)   | 0.1 |
| Nulliparous (n = 102)       | 36.4 (6.5)   | 0.6 | 36.2 (5.4)   | 0.9 |
| Parous (n = 564)            | 38.1 (4.5)   | 0.3 | 39.7 (4.2)   | 0.03 |
| Breast density (%)          | 21.1 (10.9)  | <0.0001 | 19.1 (9.2)  | 0.06 |
| Parous (yes)                | 112 (85)     | 0.6 | 27 (75)     | 0.8 |
| Postmenopausal (yes)        | 80 (61)      | 0.99 | 21 (58)     | 0.8 |
| Breast fed (ever)           | 102 (77)     | 0.7 | 25 (69)     | 0.9 |
| Alcohol consumption (ever)  | 89 (67)      | 0.4 | 30 (83)     | 0.1 |
| Hormonal therapy use (ever) | 36 (45)      | 0.3 | 5 (24)      | 0.7 |
| Oral contraceptive use (ever) | 81 (61)     | 0.4 | 21 (58)     | 0.7 |
Receiver operating characteristic curves for predicting breast cancer were calculated by estimating the mean of the transformed measures for the controls (only) to establish the population norms. We then used these population norms to derive the residuals, for both the controls and the cases, and then divided these control-based residuals by their respective standard deviations for the controls.

We used conditional logistic regression to estimate the odds ratio (OR) for a binary factor and, for each continuous variable, the change in odds per standard deviation of that variable after it had been adjusted, as above (OPERA).26 Statistical inference was based on asymptotic likelihood theory. We used the likelihood ratio test and the Bayesian information criterion (ΔBIC) to compare model fits. Strength of evidence between two models was interpreted as nonexistent if ΔBIC<2, positive if 2–6, strong if 6–10 and very strong if ≥10.27

Risk discrimination was assessed from considering log (OPERA), the risk gradient on the log-odds scale, which is the difference between case patients and control subjects in the means of their standardized and normalized risk factor adjusted for covariates. The equivalent interquartile risk ratio is approximately OPERA. Risk discrimination was also assessed by the AUC; under normality and multiplicative risk assumptions, AUC = Φ[log(OPERA)/√2], where Φ is the cumulative distribution function of the standard normal distribution. All statistical analyses were conducted using the software Stata 14.0.29

Data availability
The datasets used for the current study are available upon reasonable request from the corresponding author.

Results
Table 1 shows that case patients differed from control subjects in breast density for women with and without a family history (p = 0.06 and p < 0.0001, respectively). Having at least one first-degree relative with breast cancer was more common for case patients than control subjects (p = 0.0006).

Figure 1 shows that, for unadjusted breast density, the AUCs were 0.62 and 0.66 (standard errors ~0.02) when dichotomized about the median and when used as a continuum, respectively. (For BI-RADS as four categories, the AUC was 0.65 with χ² = 43.10). There was very strong evidence that the latter gave an improved fit compared with the two other measures (both ΔBIC≥15). The OR for the upper versus lower 50% was 3.2 (95% CI 2.1–4.8). Compared with the lowest quartile, the ORs for the second, third and fourth quartiles were 1.9 (95% CI 1.0–3.8), 3.4 (95% CI 1.8–6.5) and 5.9 (95% CI 3.1–11.2), respectively.

Table 2 shows that the OPERA for transformed and standardized breast density unadjusted for age and BMI was 1.99 (95% CI 1.61–2.46; p < 0.0001), and there were no associations with either age at mammogram (a matching variable) or BMI (both p > 0.2; analyses not shown). Table 2 also shows that, after adjustment for age and BMI, the OPERA for adjusted breast density was 2.26 (95% CI 1.81–2.81; p < 0.0001), and there was strong evidence (2ΔLL = 16) that this gave a better fit than unadjusted breast density.

Table 2. Univariable associations with risk of interval breast cancer

|                          | OPERA (95% CI) | AUC (95% CI) | χ²           | LL        |
|--------------------------|---------------|--------------|--------------|-----------|
| Breast density¹          | 1.99 (1.61–2.46) | 0.66 (0.62–0.71) | 48.36         | −201.90   |
| Age at mammogram         | 0.66 (0.36–1.19) | 0.51 (0.46–0.56) | 1.98         | −225.09   |
| Body mass index          | 1.02 (0.85–1.22) | 0.50 (0.45–0.55) | 0.05         | −226.05   |
| Adjusted breast density² | 2.26 (1.81–2.81) | 0.70 (0.65–0.74) | 66.93        | −192.62   |

¹Breast density is defined as percent mammographic density.
²Adjusted for age and body mass index.

Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval; OPERA, odds per adjusted standard deviation; χ² is the likelihood ratio test statistic.
Table 3 shows that, when fitted together, the association of adjusted breast density with interval breast cancer was unchanged after adjustment for the other factors. The association with family history was also virtually unchanged after adjustment for adjusted breast density.

Table 4 shows that there was marginal or strong evidence that the adjusted breast tissue aging association differed by family history and breast density ($p = 0.04, 0.07$ and $0.003$, respectively; see Models 1 and 2).

Table 4 also shows evidence for interactions between adjusted breast tissue aging and both adjusted breast density and family history when all three factors were fitted together (see Model 3). Fitting the two interaction terms improved the fit ($p < 0.001$) and both interaction terms were significant ($p = 0.001$ and $0.007$, respectively).

Figure 2 shows that the AUC from fitting adjusted breast density, family history and their interactions with adjusted breast tissue aging was 0.73 (95% CI 0.69–0.77), equivalent to OPERA = 2.34 and a ninefold interquartile risk ratio. This AUC was greater than 0.70 (95% CI 0.65–0.74) when using adjusted breast density alone ($p = 0.003$) and greater than 0.66 (95% CI 0.62–0.71) when using unadjusted breast density as a continuum ($p = 0.0001$).

Table 3. Univariable and multivariable associations with risk of interval breast cancer

|                    | Univariable | Multivariable |
|--------------------|-------------|---------------|
| Adjusted breast density | 2.26 (1.81–2.81) | 2.24 (1.79–2.81) |
| Family history      | 2.70 (1.66–4.39) | 2.65 (1.57–4.49) |
| Body mass index     | 1.01 (0.97–1.04) | 1.00 (0.97–1.04) |
| Adjusted breast tissue ageing | 1.17 (0.97–1.40) | 1.07 (0.87–1.30) |
| AUC                 | 0.70 (0.65–0.74) | 0.56 (0.53–0.59) |
| $\chi^2$            | 66.93        | 15.46         |
| Log likelihood      | $-192.62$    | $-218.35$     |

Note: For binary risk factors the association is an odds ratio (OR) whereas for continuous risk factors, the association is the change in odds ratio per standard deviation of the adjusted risk factor (OPERA). AUC, area under the receiver operating characteristic curve; $\chi^2$ is the likelihood ratio test statistic.

1Adjusted for age and body mass index.

Table 4. Multivariable associations (95% confidence intervals in parentheses) with risk of interval breast cancer, allowing for interactions between adjusted breast density or family history and adjusted breast tissue aging

|                    | Model 1 | Model 2 | Model 3 |
|--------------------|---------|---------|---------|
| Adjusted breast density | 2.27 (1.81–2.85) | –       | 2.36 (1.85–3.00) |
| Family history      | 2.63 (1.58–4.38) | 2.56 (1.47–4.45) |
| Adjusted breast tissue ageing | 0.90 (0.72–1.13) | 1.09 (0.88–1.33) | 0.79 (0.61–1.02) |
| AUC                 | 0.71 (0.66–0.75) | 0.58 (0.53–0.63) | 0.73 (0.69–0.77) |
| $\chi^2$            | 75.59    | 22.93   | 95.01   |
| Log likelihood      | $-188.29$ | $-214.61$ | $-178.57$ |

Abbreviations: AUC, area under the receiver operating characteristic curve; $\chi^2$ is the likelihood ratio test statistic.

Figure 2. Receiver operating characteristic curves for predicting interval breast cancer using breast density as a continuous variable unadjusted for any covariates, using breast density adjusted for age and body mass index and using the best fitting model that included interactions.
The AUCs of 0.73, 0.70 and 0.66 above correspond to log(OPERA)s of 0.86, 0.73 and 0.60, respectively, which are equivalent to IQRRs of 9.0, 6.2 and 4.5. Therefore, compared with using only unadjusted breast density, on the log(OPERA) scale the risk gradient increased by 43% from using adjusted breast density as a continuum, including family history, and allowing for interactions between age-adjusted breast tissue aging and both adjusted breast density and family history. In terms of AUC compared to 0.5, the corresponding increase was from 0.66 to 0.73 (44%). The increase from considering dense breast as a binary construct was from 0.62 to 0.73 (190%).

Discussion

We found that the ability to predict interval breast cancers might be almost doubled by considering more than unadjusted breast density dichotomized about its median, similar to how dense breasts are defined using BI-RADS. Interval cancers are either (i) potentially detectable at screening but missed (about 20–25% of all interval cancers) or (ii) nonexistent, too small, or otherwise not detected at screening but grew rapidly thereafter. Possibility (i) is more likely the greater the proportion of the breast covered by light or bright areas. Possibility (ii) is more likely the greater a woman’s underlying risk of breast cancer risk, especially that of more aggressive disease. Either way, women more likely to develop breast cancer overall are more likely to develop interval cancers.

First, unadjusted breast density was a better predictor of interval cancer than breast density dichotomized by the median for controls, analogous to the current BI-RADS classification. Second, breast density was a better predictor of interval cancer when adjusted for age and BMI. Third, having a family history of breast cancer was an important predictor of interval cancers.

Fourth, the risk associations of breast density adjusted for age and BMI and family history combine multiplicatively. This implies that, in terms of absolute risk of interval cancer, family history is more important the greater a woman’s breast density. This observation is of relevance to cancer family genetic services, and the role of breast density in predicting interval cancers for women already at increased (familial) risk deserves attention.

Fifth, a novel breast cancer risk factor which combines absolute risk information from age, age at puberty, number and timing of any live births and age at menopause (if achieved) to represent the relative risk due to exposure to estrogen and progesterone for women of the same age, interacted with breast density and family history. This suggests that, for women of the same age, their hormonal exposure is more important the greater their risk of having a tumor masked and the greater their familial risk. Including information on reproductive and familial risk factors could improve risk prediction, but not necessarily in the same way or to the same degree as it would if it was assumed it had the same risk association with breast cancer overall. In practice, whether or not to include asking women about their reproductive history could depend on whether they had high breast density or a family history.

Our finding of a more than multiplicative combination of breast tissue aging with breast density and family history, is not the only example of such interactions for interval cancers. Li et al. recently found evidence for interactions between breast density and a measure of genetic risk whereby, for women with interval cancer, those with low breast density had a greater chance of carrying a high-risk breast cancer susceptibility mutation.

Figure 1 shows that moving from dense breasts as a binary variable to breast density as a continuous variable improved sensitivity (true positivity) with little loss in specificity when specificity was high. Figure 2 shows that adding risk factor information improved specificity (true negativity) with little loss in sensitivity when sensitivity was high.

The BI-RADS classification of dense breast based on a–b vs. c–d is similar to our classification based on the median for controls. The increased risk associated with having dense breasts, defined as being in the upper half of the breast density distribution, was about threefold. Given that the incidence of interval breast cancers is about 1–2 per 1,000 women undergoing 2 yearly screening, the incidence of interval breast cancer for women with dense breasts is about 1–2 per 1,000 higher than it is for women without dense breasts. If a woman has 10 (2 yearly) screens in her lifetime and is always categorized as having dense breasts, her risk of ever having an interval breast cancer will be about 1–2% more than for a woman without dense breasts. Given that >25 million women in the US aged 40–74 years have dense breasts, dense breasts are implicated in about 25–50,000 interval cancers among these women.

Our model almost doubled the risk gradient and could be used to derive more optimal cut-offs for management strategies based on risk stratification. This empirical information could be useful for screening programs to conduct economic modeling and cost–benefit analyses. Decisions about how to use the model to inform future screening and use of other screening modalities should be based on absolute risk, not only on relative risk, so a model for the age-specific incidence of interval cancer needs to be created specifically for the population being screened.

Strengths of our study include the use of a novel risk measure based on Pike’s model of breast tissue aging and fitting interactions. We did not presume the same risk factors, with same risk gradients, applied to interval cancers as they do to breast cancer overall and found evidence that contradicted this assumption.

Weaknesses include the relatively small sample size so our risk discrimination is likely to be overestimated and there is a need for independent replication. Our findings were based on film mammograms and might not apply to digital mammograms. They were also based on only one mammogram; considering a woman’s breast density history could improve risk prediction. We based our model on information collected at...
or around the baseline, on average 5–6 years prior to diagnosis, so it is likely that the risk gradients could be even greater if predictions were over a 2-year interval after a negative screen. Finally, we only had information for family history as a binary construct and no information on genetic risk.

Risk prediction could also be substantially improved. We recently created Cirrus, a novel automated measure of breast cancer risk based on features of a mammogram, which has an OPERA of 1.7. A similar OPERA applies to a polygenic risk score based on approximately 3,000 single nucleotide polymorphic markers. We have also found that defining breast density at higher pixel brightness thresholds can give stronger risk prediction, and that familial risk could be stronger if based on a continuous measure using multigenerational pedigree data. It remains to be seen how much addition of these breast cancer risk factors might improve risk stratification.

In summary, our findings illustrate the potential for improving mammography screening. Women at increased risk of serious breast cancers that occur within regular screening intervals could be more accurately identified than by using BI-RADS alone. Information routinely collected by some mammography services could be used to better classify women in terms of risk. Triaging women for breast screening might be substantially improved by considering breast density as a continuum, adjusting it for BMI and using other measures related to risk. This would also give women with dense breasts, and their physicians, more information about the consequences of having dense breasts—an increased risk of developing an interval breast cancer, a critically important outcome for screening programs and women.

Acknowledgements
We thank the Breast Cancer Network Australia, the Victorian Cancer Registry, BreastScreen Victoria, the Australian Mammographic Density Research Facility and the participants in the Melbourne Collaborative Cohort Study. The Melbourne Collaborative Cohort Study cohort recruitment was funded by VicHealth and Cancer Council Victoria and was further augmented by Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. This research was supported by the National Health and Medical Research Council (251533, 209057 and 504711), the Victorian Health Promotion Foundation, Cancer Council Victoria, Cancer Council New South Wales, Cancer Australia, Cure Cancer Australia (1159399) and the National Breast Cancer Foundation. TLN and SL have both been supported by Victorian Cancer Council Post-Doctoral Fellowships and the Picchi Foundation—Victorian Comprehensive Cancer Centre. JS is a National Breast Cancer Foundation Research Fellow. JLE is a NHMRC Senior Principal Research Fellow. MAJ and MCS are NHMRC Senior Research Fellows. Dr. Pike receives support from the US National Institutes of Health/National Cancer Institute Cancer Institute Support Grant P30 CA008748 to Memorial Sloan Kettering Cancer Center.

References
1. McCarthy AM, Barlow WE, Conant EF, et al. Breast cancer with a poor prognosis diagnosed after screening mammography with negative results. JAMA Oncol 2018;4:998–1001.
2. Holm J, Humphreys K, Li J, et al. Risk factors and tumor characteristics of interval cancers by mammographic density. J Clin Oncol 2015;33:1030–7.
3. Houssami N, Hunter K. The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening. NPI Breast Cancer 2017;3:12.
4. Kerlikowske K, Zhu W, Tosteson AN, et al. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med 2015;162:673–81.
5. Trentham-Dietz A, Kerlikowske K, Stout NK, et al. Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: collaborative modeling of screening outcomes. Ann Intern Med 2016;165:590–12.
6. Shah Y, Eklund M, Madlensky L, et al. Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial. J Natl Cancer Inst 2017;109:djw290.
7. Lasby-Secretan B, Scocciati C, Loomis D, et al. Breast-cancer screening—viewpoint of the IARC working group. N Engl J Med 2015;372:2353–8.
8. Cappello NM. Dr. Nancy Cappello's story. Available from: https://www.areyoudense.org/stories/nancy/.
9. Dehkordy SF, Carlos RC. Dense breast legislation in the United States: state of the states. J Am Coll Radiol 2015;10:899–902.
10. Dehkordy SF, Carlos RC. Dense breast legislation in the United States: state of the states. J Am Coll Radiol 2016:13:R53–R7.
11. Cappello NM, Richetelli D, Lee CI. The impact of breast density reporting laws on women’s awareness of density-associated risks and conversations regarding supplemental screening with providers. J Am Coll Radiol 2019:16:139–46.
12. Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014;106:duj255.
13. Sprague BL, Kerlikowske K, Bowles EJ, et al. Trends in clinical breast density assessment from the breast cancer surveillance consortium. J Natl Cancer Inst 2019. https://doi.org/10.1093/jnci/djy210.
14. D’Orioi CJ, Sickles EA, Mendelson EB, et al. ACR BI-RADS atlas, breast imaging reporting and data system. Reston, VA: American College of Radiology, 2013.
15. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227–36.
16. Krishnan K, Baglietto L, Apicella C, et al. Mammographic density and risk of breast cancer by mode of detection and tumor size: a case-control study. Breast Cancer Res 2016;18:63.
17. Eriksson I, Czene K, Rosenberg LU, et al. Mammographic density and survival in interval breast cancers. Breast Cancer Res 2013; 15:R48.
18. McCormack VA, dos Santos SI, De Stavola BL, et al. Life-course body size and perimenopausal mammographic parenchymal patterns in the MRC 1946 British birth cohort. Br J Cancer 2003; 89:852–9.
19. Pike MC, Krailo MD, Henderson BE, et al. ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature 1983;303: 767–70.
20. Rooser B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' health study. Am J Epidemiol 1994;139:819–35.
21. Rice MS, Tamimi RM, Bertrand KA, et al. Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 2018;170: 129–41.
22. Ireland P, Jolley D, Giles G, et al. Development of the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort. Asia Pac J Clin Nutr 1994;3:19–31.
23. Giles GG, English DR. The Melbourne collaborative cohort study. IARC Sci Publ 2002;156: 69–70.
24. Baglietto L, Krishnan K, Stone J, et al. Associations of mammographic dense and nondense areas and body mass index with risk of breast cancer. Am J Epidemiol 2014;179:475–83.
25. Byng JW, Yaffe MJ, Jong RA, et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 1998; 18:587–98.
26. Hopper JL. Odds per adjusted standard deviation: comparing strengths of associations for risk
factors measured on different scales and across diseases and populations. Am J Epidemiol 2015; 182:863–7.
27. Kass RE, Raftery AE. Bayes factors. J Am Stat Assoc 1995;90:773–95.
28. Schmidt DF, Makalic E, Gouley B, et al. Cirrus: an automated mammography-based measure of breast cancer risk based on textural features. JNCI Cancer Spectrum 2018;2:pkry057.
29. StataCorp. Stata statistical software: Release 15. College Station, TX: StataCorp LLC, 2017.
30. Caumo F, Vecchiato F, Strabbioli M, et al. Interval cancers in breast cancer screening: comparison of stage and biological characteristics with screen-detected cancers or incident cancers in the absence of screening. Tumori 2010;96:198–201.
31. Li J, Holm J, Bergh J, et al. Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers. Ann Oncol 2015;26:517–22.
32. Mavaddat N, Michailidou K, Dennis J, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet 2019;104:21–34.
33. Nguyen TL, Aung YK, Evans CF, et al. Mammographic density defined by higher than conventional brightness thresholds better predicts breast cancer risk. Int J Epidemiol 2017;46:652–61.
34. Nguyen TL, Choi YH, Aung YK, et al. Breast cancer risk associations with digital mammographic density by pixel brightness threshold and mammographic system. Radiology 2018;286:433–42.
35. Dite GS, MacInnis RJ, Bickerstaffe A, et al. Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian breast cancer family registry. Cancer Epidemiol Biomarkers Prev 2016;25:359–65.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Nguyen, TL; Li, S; Dite, GS; Aung, YK; Evans, CF; Trinh, HN; Baglietto, L; Stone, J; Song, Y-M; Sung, J; English, DR; Jenkins, MA; Dugue, P-A; Milne, RL; Southey, MC; Giles, GG; Pike, MC; Hopper, JL

Title:
Interval breast cancer risk associations with breast density, family history and breast tissue aging

Date:
2019-11-12

Citation:
Nguyen, T. L., Li, S., Dite, G. S., Aung, Y. K., Evans, C. F., Trinh, H. N., Baglietto, L., Stone, J., Song, Y. -M., Sung, J., English, D. R., Jenkins, M. A., Dugue, P. -A., Milne, R. L., Southey, M. C., Giles, G. G., Pike, M. C. & Hopper, J. L. (2019). Interval breast cancer risk associations with breast density, family history and breast tissue aging. INTERNATIONAL JOURNAL OF CANCER, 147 (2), pp.375-382. https://doi.org/10.1002/ijc.32731.

Persistent Link:
http://hdl.handle.net/11343/245043

File Description:
published version

License:
CC BY